Use of methylene blue in the prevention of recurrent intra-abdominal postoperative adhesions.
Octavian C NeagoeMihaela IonicăOctavian MaziluPublished in: The Journal of international medical research (2017)
Objective To evaluate the efficacy of methylene blue in preventing recurrent symptomatic postoperative adhesions. Methods Patients with a history of >2 surgeries for intra-abdominal adhesion-related complications were selected for this study. Adhesiolysis surgery was subsequently performed using administration of 1% methylene blue. The follow-up period was 28.5 ± 11.1 months. Results Data were available from 20 patients (seven men and 13 women) whose mean ± SD age was 51.2 ± 11.4 years. Adhesions took longer to become symptomatic after the first abdominal surgery when the initial pathology was malignant compared with benign. However, the recurrence of adhesions after a previous adhesiolysis surgery had a similar time onset regardless of the initial disease. Following adhesiolysis surgery with methylene blue, the majority of patients did not present with symptoms associated with adhesion complications (i.e., chronic abdominal pain, bowel obstruction) for the length of the follow-up period. Conclusions The use of methylene blue during adhesiolysis surgery appears to reduce the recurrence of adhesion-related symptoms, suggesting a beneficial effect in the prevention of adhesion formation.
Keyphrases
- minimally invasive
- coronary artery bypass
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- patients undergoing
- surgical site infection
- peritoneal dialysis
- biofilm formation
- escherichia coli
- electronic health record
- cell migration
- abdominal pain
- coronary artery disease
- machine learning
- cystic fibrosis
- patient reported outcomes
- atrial fibrillation
- candida albicans